Bio‑Techne and Oxford Nanopore extended and broadened their collaboration to develop and commercialize targeted enrichment long‑read sequencing kits for screening and diagnosing heritable genetic disorders. The expanded deal, which runs through 2032, gives Bio‑Techne commercial rights to a wider portfolio beyond the carrier screening assay already launched and signals a push to move nanopore long‑read technologies deeper into clinical genetics. Company leaders emphasized coordinated data sharing and chemistry improvements to support broader productization.